- Home
- ORMP vs ABOS Comparison
ORMP vs ABOS Comparison
Compare ORMP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | ABOS |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 197.9M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORMP | ABOS |
|---|---|---|
| Price | $4.11 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 516.0K | ★ 685.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.45 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.19 |
| 52 Week High | $5.19 | $3.60 |
Technical Indicators
Market Signals| Indicator | ORMP | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 38.07 |
| Support Level | $3.69 | $1.59 |
| Resistance Level | $4.22 | $2.43 |
| Average True Range (ATR) | 0.28 | 0.20 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 16.67 | 3.55 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.